The trajectory of companies tied to flagship drugs like Viagra presents a nuanced investment landscape . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial profits , the loss of exclusivity in key regions has introduced significant risk . Investors are now facing the consequences of rival medica